[Evaluation of the therapeutic effects of broncaspin in chronic bronchopneumopathies].
A controlled single-blind clinical trial was made with Broncaspin, on original synthetic molecule obtained by condensing acetylsalicylic acid and guaiacol, in a comparison of its local and general tolerance, and antipyretic, antiexudative and balsamic properties with those of dimethylaminophenazone guaiacolglycolate, a well-known preparation, in two randomly composed groups of 15 patients with chronic obstructive bronchial and lung diseases, using 1,2 g Broncaspin suppositories and the commercial form of the other product twice a day for 14 consecutive days. Therapeutic assessment was based on the symptomatological, spirometric and blood gas data.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000632:Aminopyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001982:Bronchial Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D006139:Guaiacol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D012119:Respiration / Q000187:drug effects; D013147:Spirometry
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D000632:Aminopyrine; D006139:Guaiacol; D001241:Aspirin; C023557:guacetisal
Valutazione degli effetti terapeutici del "Broncaspin" nei broncopneumopatici cronici.